Talphera Inc. - Asset Resilience Ratio
Talphera Inc. (TLPH) has an Asset Resilience Ratio of 48.75% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TLPH FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Talphera Inc.'s Asset Resilience Ratio has changed over time. See Talphera Inc. (TLPH) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Talphera Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Talphera Inc. worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.49 Million | 48.75% |
| Total Liquid Assets | $14.49 Million | 48.75% |
Asset Resilience Insights
- Very High Liquidity: Talphera Inc. maintains exceptional liquid asset reserves at 48.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Talphera Inc. Industry Peers by Asset Resilience Ratio
Compare Talphera Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Talphera Inc. (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Talphera Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.75% | $14.49 Million | $29.72 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $18.24 Million | -- |
| 2023-12-31 | 17.95% | $3.66 Million | $20.39 Million | +16.90pp |
| 2022-12-31 | 1.04% | $495.00K | $47.49 Million | -48.98pp |
| 2021-12-31 | 50.03% | $38.97 Million | $77.89 Million | +26.48pp |
| 2020-12-31 | 23.55% | $15.61 Million | $66.30 Million | -32.77pp |
| 2019-12-31 | 56.32% | $51.45 Million | $91.36 Million | +41.60pp |
| 2018-12-31 | 14.72% | $17.74 Million | $120.53 Million | +4.70pp |
| 2017-12-31 | 10.02% | $7.57 Million | $75.55 Million | +5.68pp |
| 2015-12-31 | 4.34% | $5.54 Million | $127.78 Million | -13.38pp |
| 2014-12-31 | 17.72% | $15.31 Million | $86.42 Million | +3.85pp |
| 2013-12-31 | 13.87% | $15.26 Million | $110.03 Million | -4.47pp |
| 2012-12-31 | 18.34% | $11.83 Million | $64.52 Million | -50.21pp |
| 2011-12-31 | 68.55% | $27.99 Million | $40.84 Million | +59.37pp |
| 2010-12-31 | 9.18% | $627.00K | $6.83 Million | -28.06pp |
| 2009-12-31 | 37.24% | $5.40 Million | $14.49 Million | -25.09pp |
| 2008-12-31 | 62.33% | $14.13 Million | $22.68 Million | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more